अApnaFunda

FORTIS HEALTHCARE LIMITED (FORTIS)

Health Services · Hospital/Nursing Management · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.46 / 100
Profitability 41Growth 49Balance sheet 49
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.46 / 100
Price 18Earnings 51FII/DII 69

Share price

Closing priceAdjusted for splits and bonus issues.

₹774.55 latest close · −20.5% over the last 90 sessions

₹700₹800₹900₹1,000Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹700₹800₹900₹1,000Jul 3Sep 4Nov 9

₹774.55 month-end · −15.7% over 12 months

₹800₹900Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹800₹900Nov '25May '26Nov '26

₹774.55 month-end · +100.7% over 3 years

₹400₹600₹800₹1,000Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹400₹600₹800₹1,000Nov '23May '25Nov '26

₹774.55 month-end · +472.9% since Jan '19

₹500₹1,000Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹500₹1,000Jan '19Dec '22Nov '26

52-week range ₹704.95 to ₹1034.50 · 1-year volatility 27.2%

Was the rally earned?

-16%share price, 1 yearLower P/E held it back

Earnings helped, the multiple did not.

  • Per-share earnings added 17 points, but investors now pay less per rupee of profit (P/E 79.9x to 55.8x), which took 33 points back.
  • The share count fell 4%.
Net profit growth: +14 pts. Points of the price return explained by net profit growing (or shrinking).+14 ptsNet profit growthP/E change: −33 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−33 ptsP/E changeShare count change: +3 pts. Points of the price return explained by the share count changing. More shares count against the price.+3 ptsShare count changeShare price: −16%−16%Share priceNet profit growth: +14 pts. Points of the price return explained by net profit growing (or shrinking).+14ProfitP/E change: −33 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−33P/EShare count change: +3 pts. Points of the price return explained by the share count changing. More shares count against the price.+3SharesShare price: −16%−16%Share price
Net profit growth+14 ptsNet profit rose about 16%, which lifts the price.
P/E change-33 ptsThe P/E fell from 79.9x to 55.8x, which lowers the price.
Share count change+3 ptsShare count fell 4%, which lifts the price.
+101%share price, 3 yearsEarnings-driven

Mostly yes.

  • Per-share earnings added 83 points to the rise, while the multiple moved less (P/E 49.5x to 55.8x).
  • The share count fell 7%.
Net profit growth: +73 pts. Points of the price return explained by net profit growing (or shrinking).+73 ptsNet profit growthP/E change: +17 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+17 ptsP/E changeShare count change: +10 pts. Points of the price return explained by the share count changing. More shares count against the price.+10 ptsShare count changeShare price: +101%+101%Share priceNet profit growth: +73 pts. Points of the price return explained by net profit growing (or shrinking).+73ProfitP/E change: +17 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+17P/EShare count change: +10 pts. Points of the price return explained by the share count changing. More shares count against the price.+10SharesShare price: +101%+101%Share price
Net profit growth+73 ptsNet profit rose about 66%, which lifts the price.
P/E change+17 ptsThe P/E rose from 49.5x to 55.8x, which lifts the price.
Share count change+10 ptsShare count fell 7%, which lifts the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with APOLLO HOSPITALS ENTERPRISES L

How rough has the ride been?

Maximum drawdown-35.1%not yet recovered
1-year volatility27.2%annualised
Beta vs sector index0.853-year daily, correlation 0.48
Volume spikes2last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−10%−20%−30%2020202120222023202420252026−35.1% 0%−10%−20%−30%2020202220242026−35.1%
Largest drawdowns

-35.1% (2025-10 peak to 2026-10 low, not yet recovered)

-31.0% (2020-02 peak to 2020-05 low, recovered 2021-01)

-27.0% (2022-01 peak to 2022-06 low, recovered 2022-09)

Most recent volume spikes

2026-10-01: 7x the 50-day median, price +1.9% that day

2026-09-30: 6x the 50-day median, price -6.3% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

55.8xP/E todayWithin its usual range
Against its own history38th percentile
CheapestMedian 66.5xDearest

Usual range 37.8x to 187.6x since 2019-01.

Against Health Services55.8x vs 50.9x
This company
55.8x
Sector median
50.9x

10% above the Health Services median.

29.7x118.4x207.0x295.6xJan '19Aug '20Mar '22Oct '23May '25Nov '2629.7x118.4x207.0x295.6xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Services median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Services is valued

Where does it rank among Health Services peers?

Each cell is the company's percentile rank among its Health Services peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE35th▼ 4 pts vs a year ago
  • Op. margin47th▼ 9 pts vs a year ago
  • Revenue growth45th▼ 5 pts vs a year ago
  • EPS growth62nd▼ 14 pts vs a year ago
  • Debt/equity ↓44th▼ 11 pts vs a year ago
  • Cash cycle ↓84thflat vs a year ago
  • P/E ↓47th▲ 23 pts vs a year ago
  • 12M momentum37th▼ 39 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Services sector page Watch it move against Health Services in the Observatory

What is the price implying?

~31%annual earnings growth implied by the price

At a P/E of 75.8x, the price would imply about 31.2%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Services The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹774.55
P/E
55.8x
ROCE
13.0%
Market Cap
₹58487 cr
Revenue (TTM)
₹9506 cr
P/S
6.2x
P/B
5.9x
ROE
10.6%
Operating Margin
21.0%
Debt / Equity
0.4x
Promoter Holding
31.2%
12M Momentum
-15.7%

52-week range

₹704.95₹1034.50
21% of the way from its 52-week low to its high

Price risk

1Y volatility
27.2%
Beta vs sector
1-year daily
1.02

Balance sheet & cash

Interest cover
operating profit ÷ interest
5.2x
Cash from profit, 3Y
operating cash flow ÷ net profit
1.64x
Share count, 1Y
unchanged

Are profits backed by cash?

7 of 7checks within rangeAll clear
Other income reliance3%Within range

Other income as a share of pre-tax profit (trailing twelve months): 3.0%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate24%Within range

Median quarterly effective tax rate over about 2.5 years: 24.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion1.64xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.64x (cash from operations ₹4,125 cr, net profit ₹2,518 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow5 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+8 daysWithin range

Debtor days are above the median of the previous three fiscal years by 8 days (42 vs 34). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress4% of fixed assetsWithin range

Capital work-in-progress is 4% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+1 days / 2 yrsWithin range

Days payable changed by +1 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, DIIs added 5.7 pts; FIIs trimmed 1.1 pts.
  • The number of shareholders rose from 1.3 lakh to 2.2 lakh (+68%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters31.2%31.2%0.0 pts
FIIs26.3%25.2%-1.1 pts
DIIs26.6%32.2%+5.7 pts
Public and others16.0%11.4%-4.6 pts

Number of shareholders

2.2 lakhshareholders+68% since Sep '23
1.3L1.7L2.0L2.3L Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 1.3 lakh
Dec '23: 1.4 lakh
Mar '24: 1.6 lakh
Jun '24: 1.5 lakh
Sep '24: 2.0 lakh
Dec '24: 2.2 lakh
Mar '25: 2.2 lakh
Jun '25: 2.1 lakh
Sep '25: 2.2 lakh
Dec '25: 2.3 lakh
Mar '26: 2.3 lakh
Jun '26: 2.2 lakh
1.3L1.7L2.0L2.3L Sep '23Sep '24Sep '25Jun '26
Sep '23: 1.3 lakh
Dec '23: 1.4 lakh
Mar '24: 1.6 lakh
Jun '24: 1.5 lakh
Sep '24: 2.0 lakh
Dec '24: 2.2 lakh
Mar '25: 2.2 lakh
Jun '25: 2.1 lakh
Sep '25: 2.2 lakh
Dec '25: 2.3 lakh
Mar '26: 2.3 lakh
Jun '26: 2.2 lakh

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−1.5%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like FORTIS HEALTHCARE LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −19% to +26% vs the market, against −4% for all non-financial companies in the same months.
  • The gap against the base rate (+2.2%, 80% range −7.4% to +12.2%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−60%−40%−20%0%+20%+40%+60%+80%+100%
EIHOTEL · Feb 2020: −46.1% vs market
ZYDUSLIFE · May 2021: −43.4% vs market
BERGEPAINT · Dec 2023: −36.9% vs market
SYMPHONY · Apr 2023: −33.4% vs market
SFL · Aug 2022: −31.3% vs market
NEOGEN · Feb 2023: −30.1% vs market
JYOTHYLAB · Aug 2020: −28.5% vs market
SUNDRMFAST · Nov 2023: −28.0% vs market
BIOCON · Jul 2022: −27.0% vs market
TORNTPHARM · Jan 2021: −24.7% vs market
ZYDUSWELL · Jun 2021: −22.1% vs market
SHREECEM · Jul 2023: −22.0% vs market
AARTIIND · Jun 2021: −19.9% vs market
BALKRISIND · Aug 2023: −17.3% vs market
ULTRACEMCO · Apr 2021: −14.6% vs market
GODREJCP · Jun 2025: −14.5% vs market
CROMPTON · Jun 2024: −14.2% vs market
VGUARD · Aug 2024: −14.1% vs market
UNITDSPR · Jan 2022: −10.7% vs market
METROBRAND · Mar 2025: −9.1% vs market
RAMCOCEM · Aug 2020: −8.6% vs market
RAINBOW · Oct 2025: −5.9% vs market
MEDANTA · Jan 2025: −4.4% vs market
SYNGENE · Nov 2023: −3.3% vs market
APOLLOHOSP · Aug 2023: −2.3% vs market
TATACONSUM · Jun 2024: −0.7% vs market
UNOMINDA · Jan 2023: +1.7% vs market
ALKEM · Apr 2024: +4.2% vs market
ANURAS · Jul 2022: +6.7% vs market
OBEROIRLTY · Apr 2023: +9.7% vs market
MANKIND · Oct 2025: +10.5% vs market
METROPOLIS · Mar 2025: +14.0% vs market
CONCOR · Nov 2021: +14.0% vs market
SUNPHARMA · Feb 2020: +17.1% vs market
INDHOTEL · Jun 2024: +19.1% vs market
FLUOROCHEM · Oct 2025: +19.9% vs market
ELGIEQUIP · Feb 2020: +22.9% vs market
BIKAJI · Feb 2024: +26.7% vs market
TITAN · Jul 2021: +27.5% vs market
NH · Feb 2021: +32.4% vs market
MAXHEALTH · Aug 2022: +38.7% vs market
RADICO · Oct 2023: +40.3% vs market
BHARATFORG · Mar 2025: +47.2% vs market
ABB · Jul 2021: +49.7% vs market
CIPLA · Jan 2020: +55.2% vs market
KIMS · Jun 2024: +58.3% vs market
THERMAX · Jun 2023: +60.1% vs market
IPCALAB · Oct 2025: +60.3% vs market
SRF · May 2021: +75.0% vs market
VBL · Dec 2021: +115.4% vs market
Similar setups −1.5%All companies −3.7%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge

Similar setups' median
−1.5%
All companies' median
−3.7%
Beat the market
48% vs 46%

50 past situations · 50 companies · 31 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
SYNGENE
Commercial Services
Nov 2023 65x15% +24%−11% −3%
AARTIIND
Process Industries
Jun 2021 58x13% +87%−5% −20%
FLUOROCHEM
Process Industries
Oct 2025 66x10% −13%−17% +20%
RAMCOCEM
Non-Energy Minerals
Aug 2020 27x12% −5%−20% −9%
TATACONSUM
Consumer Non-Durables
Jun 2024 93x11% +28%−13% −1%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
ZYDUSLIFE
Health Technology
May 2021 54x11% +79%−4% −43%
MANKIND
Health Technology
Oct 2025 51x17% −11%−21% +11%
SHREECEM
Non-Energy Minerals
Jul 2023 69x9% +18%−9% −22%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and P/S. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to FORTIS HEALTHCARE LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

Consumer Services
76%similar
revenueP/E
Retail Trade
70%similar
market caprevenue
JK CEMENTJKCEMENT
Non-Energy Minerals
68%similar
revenue growthmarket cap
Producer Manufacturing
67%similar
market cappromoter holding
Consumer Non-Durables
66%similar
revenue growthpromoter holding
Health Services
79%similar
promoter holdingoperating margin
Health Services
76%similar
volatilityrevenue
Health Services
68%similar
P/Epromoter holding

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Aug '21

  1. OctPriceFell 35% from the Oct 2025 peak to the Oct 2026 low.
  2. OctPriceVolume reached 7.0x its 50-day median on 2026-10-01; price +1.9% that day.
  3. SepPeer rankSlipped to the 3rd quartile of Health Services on operating margin (from the 2nd quartile).
  4. SepPriceVolume reached 6.0x its 50-day median on 2026-09-30; price -6.3% that day.
  5. JunPeer rankMoved into the 2nd quartile of Health Services on operating margin (from the 3rd quartile).
  6. JunPriceVolume reached 6.1x its 50-day median on 2026-06-29; price -0.5% that day.
  7. AprPeer rankSlipped to the 3rd quartile of Health Services on operating margin (from the 2nd quartile).
  8. MarPeer rankSlipped to the 2nd quartile of Health Services on EPS growth (from the top quartile).
Show 22 earlier events
  1. NovPriceVolume reached 29.0x its 50-day median on 2025-11-24; price +0.1% that day.
  2. SepPeer rankMoved into the 2nd quartile of Health Services on operating margin (from the 3rd quartile).
  3. AugPriceVolume reached 6.4x its 50-day median on 2025-08-07; price +3.0% that day.
  4. MayPriceVolume reached 7.9x its 50-day median on 2025-05-22; price +7.7% that day.
  5. MarPriceVolume reached 7.3x its 50-day median on 2025-03-21; price +0.1% that day.
  6. FebPeer rankMoved into the 2nd quartile of Health Services on EPS growth (from the 3rd quartile).
  7. SepPeer rankSlipped to the 3rd quartile of Health Services on operating margin (from the 2nd quartile).
  8. AugPeer rankSlipped to the 3rd quartile of Health Services on EPS growth (from the 2nd quartile).
  9. JunResultsRevenue (TTM) reached a new high of ₹6,893 cr.
  10. JunPeer rankMoved into the 3rd quartile of Health Services on ROCE (from the bottom quartile).
  11. JunResultsRevenue (TTM) reached a new high of ₹6,298 cr.
  12. JunPeer rankSlipped to the bottom quartile of Health Services on ROCE (from the 3rd quartile).
  13. JunDividendStarted paying a dividend (payout 13% of profit).
  14. JunPriceVolume reached 5.3x its 50-day median on 2023-06-15; price +4.3% that day.
  15. NovPriceVolume reached 14.0x its 50-day median on 2022-11-14; price +7.7% that day.
  16. SepPriceRegained the 2022-01 peak, 3 months after the low.
  17. SepPriceVolume reached 48.6x its 50-day median on 2022-09-22; price -14.7% that day.
  18. JunResultsEPS (TTM) turned positive.
  19. JunPriceFell 27% from the Jan 2022 peak to the Jun 2022 low.
  20. JunPeer rankMoved into the 3rd quartile of Health Services on ROCE (from the bottom quartile).
  21. NovPriceVolume reached 5.5x its 50-day median on 2021-11-17; price +0.3% that day.
  22. AugPriceVolume reached 12.3x its 50-day median on 2021-08-20; price +3.7% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1155.8x₹9506 cr10.6%13.0%0.4x
2026-1055.3x₹9506 cr10.8%13.0%0.4x
2026-0955.5x₹9506 cr10.8%13.0%0.4x
2026-0865.7x₹9128 cr10.8%13.0%0.4x
2026-0768.5x₹9128 cr10.8%13.0%0.4x
2026-0669.3x₹9128 cr10.8%13.0%0.4x
2026-0573.0x₹8770 cr11.0%12.0%0.3x
2026-0472.6x₹8770 cr11.0%12.0%0.3x
2026-0362.5x₹8770 cr11.0%12.0%0.3x
2026-0270.2x₹8433 cr11.6%12.0%0.3x
2026-0163.4x₹8433 cr11.6%12.0%0.3x
2025-1265.8x₹8433 cr11.6%12.0%0.3x
2025-1179.9x₹8090 cr10.1%12.0%0.3x
2025-1088.9x₹8090 cr10.1%12.0%0.3x
2025-0984.3x₹8090 cr10.1%12.0%0.3x
2025-0888.8x₹7782 cr9.1%12.0%0.3x
2025-0783.6x₹7782 cr9.1%12.0%0.3x
2025-0677.4x₹7782 cr9.1%12.0%0.3x
2025-0569.3x₹7561 cr10.8%10.0%0.2x
2025-0467.3x₹7561 cr10.8%10.0%0.2x
2025-0368.5x₹7561 cr10.8%10.0%0.2x
2025-0270.5x₹7313 cr9.2%10.0%0.2x
2025-0173.7x₹7313 cr9.2%10.0%0.2x
2024-1282.8x₹7313 cr9.2%10.0%0.2x
2024-1176.2x₹7095 cr9.1%10.0%0.2x
2024-1072.2x₹7095 cr9.1%10.0%0.2x
2024-0971.1x₹7095 cr9.1%10.0%0.2x
2024-0869.6x₹6893 cr8.4%10.0%0.2x
2024-0763.3x₹6893 cr8.4%10.0%0.2x
2024-0659.9x₹6893 cr8.4%10.0%0.2x
2024-0560.9x₹6298 cr8.7%10.0%0.1x
2024-0456.2x₹6298 cr8.7%10.0%0.1x
2024-0353.9x₹6298 cr8.7%10.0%0.1x
2024-0252.3x₹6298 cr8.7%10.0%0.1x
2024-0155.4x₹6298 cr8.7%10.0%0.1x
2023-1253.7x₹6298 cr8.7%10.0%0.1x
2023-1149.5x₹6298 cr8.7%10.0%0.1x
2023-1041.4x₹6298 cr8.7%10.0%0.1x
2023-0943.6x₹6298 cr8.7%10.0%0.1x
2023-0842.5x₹6298 cr8.7%10.0%0.1x
2023-0744.3x₹6298 cr8.7%10.0%0.1x
2023-0640.4x₹6298 cr8.7%10.0%0.1x
2023-0537.4x₹5718 cr12.8%10.0%0.2x
2023-0435.5x₹5718 cr12.8%10.0%0.2x
2023-0335.4x₹5718 cr12.8%10.0%0.2x
2023-0236.4x₹5718 cr12.8%10.0%0.2x
2023-0138.3x₹5718 cr12.8%10.0%0.2x
2022-1238.9x₹5718 cr12.8%10.0%0.2x
2022-1139.5x₹5718 cr12.8%10.0%0.2x
2022-1037.7x₹5718 cr12.8%10.0%0.2x
2022-0935.9x₹5718 cr12.8%10.0%0.2x
2022-0840.0x₹5718 cr12.8%10.0%0.2x
2022-0737.9x₹5718 cr12.8%10.0%0.2x
2022-0632.7x₹5718 cr12.8%10.0%0.2x
2022-05—₹4030 cr-0.9%2.0%0.3x
2022-04—₹4030 cr-0.9%2.0%0.3x
2022-03—₹4030 cr-0.9%2.0%0.3x
2022-02—₹4030 cr-0.9%2.0%0.3x
2022-01—₹4030 cr-0.9%2.0%0.3x
2021-12—₹4030 cr-0.9%2.0%0.3x
2021-11—₹4030 cr-0.9%2.0%0.3x
2021-10—₹4030 cr-0.9%2.0%0.3x
2021-09—₹4030 cr-0.9%2.0%0.3x
2021-08—₹4030 cr-0.9%2.0%0.3x
2021-07—₹4030 cr-0.9%2.0%0.3x
2021-06—₹4030 cr-0.9%2.0%0.3x
2021-05295.6x₹4632 cr1.4%4.0%0.2x
2021-04273.6x₹4632 cr1.4%4.0%0.2x
2021-03258.6x₹4632 cr1.4%4.0%0.2x
2021-02205.6x₹4632 cr1.4%4.0%0.2x
2021-01209.8x₹4632 cr1.4%4.0%0.2x
2020-12201.6x₹4632 cr1.4%4.0%0.2x
2020-11196.0x₹4632 cr1.4%4.0%0.2x
2020-10163.1x₹4632 cr1.4%4.0%0.2x
2020-09175.7x₹4632 cr1.4%4.0%0.2x
2020-08172.5x₹4632 cr1.4%4.0%0.2x
2020-07179.2x₹4632 cr1.4%4.0%0.2x
2020-06158.4x₹4632 cr1.4%4.0%0.2x
2020-05—₹4469 cr-3.4%6.0%0.3x
2020-04—₹4469 cr-3.4%6.0%0.3x
2020-03—₹4469 cr-3.4%6.0%0.3x
2020-02—₹4469 cr-3.4%6.0%0.3x
2020-01—₹4469 cr-3.4%6.0%0.3x
2019-12—₹4469 cr-3.4%6.0%0.3x
2019-11—₹4469 cr-3.4%6.0%0.3x
2019-10—₹4469 cr-3.4%6.0%0.3x
2019-09—₹4469 cr-3.4%6.0%0.3x
2019-08—₹4469 cr-3.4%6.0%0.3x
2019-07—₹4469 cr-3.4%6.0%0.3x
2019-06—₹4469 cr-3.4%6.0%0.3x
2019-05—₹4561 cr-23.0%3.0%0.5x
2019-04—₹4561 cr-23.0%3.0%0.5x
2019-03—₹4561 cr-23.0%3.0%0.5x
2019-02—₹4561 cr-23.0%3.0%0.5x
2019-01—₹4561 cr-23.0%3.0%0.5x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback